Zeto's wireless EEG machine

News

News

Zeto Unveils NeuroPulse, the First AI-Powered Status Epilepticus Software Using Full 10-20 EEG in Collaboration with encevis

SANTA CLARA, Calif., April 2, 2025 /PRNewswire/ — Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and advanced cloud platform, announces the integration of live bedside AI-powered Seizure Burden and Status Epilepticus detection. Utilizing encevis, a leading FDA-cleared EEG analysis software developed by the Austrian Institute of Technology, this new capability enhances EEG monitoring with automated detection and notifications for Status Epilepticus—a life-threatening, prolonged seizure condition requiring immediate intervention.

Up to one-third of neurological critical care and emergency department patients are at risk for seizures, which can lead to permanent brain injury and increased mortality risk1. Access to timely EEG interpretation remains an unmet need, particularly in emergency and critical care settings, where rapid and reliable medical intervention is essential.2

“Our product development has been guided by neurologists, critical and emergency care physicians who sought rapid, clinical-grade EEG with full-head coverage and video to not miss clinically relevant events3. They emphasized the need for accurate bedside seizure detection that enables real-time review and validation by neurologists, ensuring patients receive timely and appropriate treatment,” said Aswin Gunasekar, Founder and CEO of Zeto, Inc. “We introduced the Zeto ONE, a best-in-class, full 10-20 EEG system offering rapid setup, video, and remote reading services—being fast embraced by U.S. hospitals. With the addition of AI-powered seizure detection, we now offer a comprehensive, all-in-one solution that significantly enhances neurocritical assessment.”

encevis utilizes a cutting-edge AI model to detect seizures, seizure burden, and electrographic status epilepticus. Trained on a diverse dataset of over 21,400 hours of EEG recordings from more than 800 patients, the model was further validated using an independent dataset from 81 patients. Expert reviewers from top U.S. and European institutions meticulously labeled the data, ensuring highly accurate and clinically meaningful insights.

“We are delighted to continue our successful partnership with Zeto,” said Dr. Tilmann Kluge, Head of Medical Signal Analysis at AIT Austrian Institute of Technology. “Our algorithms allow physicians to detect seizure burden and electrographic status epilepticus early and with high sensitivity without the need for continuous expert monitoring of the EEG. Our EEG analysis software has been utilized by leading hospitals for over a decade, with capabilities such as artifact reduction, spike and seizure detection with high sensitivity and specificity.”

Zeto’s full 10-20 EEG platform now features AI-powered seizure burden detection with advanced EEG analysis tools providing comprehensive clinical value for ICU Monitoring as required by ACNS, the American Clinical Neurophysiology Society. Supported by nationwide neurologist reading services, hospitals can expand EEG access without additional infrastructure. More healthcare providers are adopting rapid EEG-powered diagnostics, enabling timely, life-saving decisions.

To learn more about how Zeto’s solutions can be integrated into your hospital, contact us at sales@zetoinc.com.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology company, is at the forefront of advancing EEG brain monitoring and diagnostics in healthcare. Through its innovative wearable devices, Zeto makes brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices, and at home. Backed by a powerful cloud-based platform, Zeto delivers nationwide monitoring and interpretation services by neurologists, along with AI-driven notifications for conditions such as seizures and epilepsy. Looking ahead, Zeto plans to expand its capabilities to detect and manage conditions like depression, stroke and traumatic brain injury. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

About Medical Signal Analysis at AIT (Austrian Institute of Technology)

Medical Signal Analysis at AIT is dedicated to the development of powerful algorithm and medical software solutions for the analysis of neurophysiological data. As part of the Austrian Institute of Technology, Austria’s largest non-university research institute, the team of researchers and software professionals developed the CE certified and FDA cleared EEG analysis software suite ‘encevis‘ which is included in EEG platforms in Europe and the US The algorithms and software for Zeto, Inc., are the most recent developments.

1 Kozak, R., et al. (2023). JACEP Open. 4(4)
2 Herman, S.T., et al. (2015) J Clin Neurophysiol. 32(2):87-95
3 Rubin MN, et al. Neurohospitalist (2014) PMID: 24381704; PMCID: PMC3869310

Source – PRNewswire

Zeto, Inc., Secures $31 Million In Series B Funding To Redefine The Future Of EEG Brain Monitoring

SANTA CLARA, Calif., Jan. 8, 2025 /PRNewswire/ — Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and AI-driven cloud platform, has announced the recent successful closing of a $31 million funding round.

The funding round was led by MindWorks Global (MWG), a Michigan-based investment entity funded by visionary entrepreneur-investors with a track record of building multi-billion-dollar enterprises. MWG’s Founder, CEO and Lead Partner, Mike Williams, is an accomplished entrepreneur and investor known for his expertise in scaling companies across different industries, including achieving a $1.1 billion exit from his most recent venture. Mike Williams said, “Zeto’s vision and technology are truly transformative for the medical arena and beyond, and we are excited to leverage our expertise and network to help drive the company’s growth. The world of EEG is going to be transformed immensely in the upcoming years, and Zeto is going to be at the forefront of it. Brain health assessment will extend beyond traditional healthcare, and we’re excited to support Zeto in pioneering new frontiers. It’s an exciting day!”

Aswin Gunasekar, Zeto’s Founder and CEO said, “Zeto has reached a pivotal milestone, earning a reputation for game-changing innovation and experiencing rapid adoption of our solutions by leading healthcare institutions across the U.S. Our management team has long aspired to collaborate with accomplished entrepreneur-investors who have successfully scaled companies to drive meaningful societal impact and significant revenue. We are excited to welcome MindWorks Global partners to our board of directors who bring not only capital but also invaluable expertise, extensive experience, and a powerful network. Our dedicated team is eager to embark on this exciting next chapter in our company’s journey.”

Zeto is grateful for the steadfast support and continued investments from its prior investors over the years. This new funding will enable Zeto to expand its commercial and operational teams, drive further growth and strengthen ongoing research and development efforts.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology company, is at the forefront of advancing EEG brain monitoring and diagnostics in healthcare. Through its innovative wearable devices, Zeto makes brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices, and at home. Backed by a powerful cloud-based platform, Zeto delivers nationwide monitoring and interpretation services by neurologists, along with AI-driven notifications for conditions such as seizures and epilepsy. Looking ahead, Zeto plans to expand its capabilities to detect and manage conditions like depression, stroke and traumatic brain injury. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – PRNewswire

Zeto Among America’s Fastest-Growing Private Companies on the 2024 Inc. 5000 List

NEW YORK, August 13, 2024 – Inc. revealed today that Zeto, Inc. ranks No. 1311 on the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses. Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, Patagonia, and many other household-name brands gained their first national exposure as honorees on the Inc. 5000.

“We are truly honored to be recognized on the Inc. 5000 list of America’s fastest-growing companies. This achievement reflects the dedication and hard work of the entire Zeto team. With the recent FDA 510(k) clearance of our groundbreaking next-generation EEG brain monitoring product, Zeto ONE, we are confident that our growth will continue as we advance EEG monitoring in critical care, outpatient, and home settings. The market potential for our solutions is enormous, offering significant opportunities for continued growth and impact,” stated Aswin Gunasekar, Founder and CEO of Zeto.

The Inc. 5000 class of 2024 represents companies that have driven rapid revenue growth while navigating inflationary pressure, the rising costs of capital, and seemingly intractable hiring challenges. Among this year’s top 500 companies, the average median three-year revenue growth rate is 1,637 percent. In all, this year’s Inc. 5000 companies have added 874,458 jobs to the economy over the past three years.

For complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria, go to www.inc.com/inc5000. All 5000 companies are featured on Inc.com starting Tuesday, August 13, and the top 500 appear in the new issue of Inc. magazine, available on newsstands beginning Tuesday, August 20.

“One of the greatest joys of my job is going through the Inc. 5000 list,” says Mike Hofman, who recently joined Inc. as editor-in-chief. “To see all of the intriguing and surprising ways that companies are transforming sectors, from health care and AI to apparel and pet food, is fascinating for me as a journalist and storyteller. Congratulations to this year’s honorees, as well, for growing their businesses fast despite the economic disruption we all faced over the past three years, from supply chain woes to inflation to changes in the workforce.”

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology firm, is at the forefront of advancing EEG brain monitoring and diagnostics for healthcare. Offering wearable devices, Zeto makes brain monitoring accessible across various clinical settings including the ICU, ED, hospital, office, and home. Supported by a feature-rich cloud-based platform, Zeto provides nationwide monitoring and interpretation services rendered by neurologists, alongside AI-enabled notifications for conditions such as seizures and epilepsy. Zeto plans to expand its capabilities in the future to recognize and manage conditions such as depression and traumatic brain injury. 

More about Inc. and the Inc. 5000

Methodology

Companies on the 2024 Inc. 5000 are ranked according to percentage revenue growth from 2020 to 2023. To qualify, companies must have been founded and generating revenue by March 31, 2020. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2023. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2020 is $100,000; the minimum for 2023 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places.

About Inc.

Inc. Business Media is the leading multimedia brand for entrepreneurs. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.’s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, print, digital, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com.

Source – PRNewswire

Zeto obtains FDA 510(k) clearance for its groundbreaking next-generation EEG brain monitoring product, ONE.

SANTA CLARA, Calif., June 4, 2024 /PRNewswire/ — Zeto, Inc., a privately owned medical technology company, has announced that its innovative next-generation product, named the ONE, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Zeto ONE is approved for EEG Brain Monitoring across hospital, home, ambulance, and air transport environments.

Electroencephalography (EEG) needs in health care remain significantly unmet due to permanent shortage of trained EEG technologists. New EEG products need to be easy to use for any staff, comfortable to the patient and provide excellent signal quality. However, hospitals also require comprehensive full-montage1,2 EEG for thorough coverage of clinically significant events, video capabilities to aid physicians in interpretation, and dependable diagnostic software for neurological emergencies. Without these elements, genuine progress in neurological care will remain unrealized.

ONE consists of a user-friendly headset equipped with 21 soft-tip electrodes positioned according to the commonly followed 10-20 EEG3 system, accompanied by intuitive LED feedback for easy adjustments. It requires minimal training for any healthcare professional to operate effectively. The portable recording device captures patient video and audio, offering display and recording controls, as well as AI-enabled notifications for seizure activity4, crucial in critical or emergency scenarios5,6. ONE seamlessly streams data to the Zeto Cloud, enabling live remote interpretations by board-certified neurologists. In addition to its role as a point-of-care system, it serves as a comprehensive EEG platform, enabling various tasks such as workflow management, patient scheduling, and report generation.

Susan Herman, M.D., Professor and Vice Chair of Clinical Affairs, Department of Neurology at Barrow Neurological Institute said, “Zeto ONE is a breakthrough EEG system, revolutionizing many aspects of emergency EEG acquisition. We know that up to 40% of brain injured emergency department and intensive care patients may experience seizures, which are often subclinical and require EEG for diagnosis. ONE fills a gap for hospitals that lack EEG resources – provides streamlined point-of care application of full 10-20 electrodes, video and audio recording, AI triage tools, and efficient connectivity to the interpreting neurologist. This enhanced workflow ensures that EEGs have high technical quality and accurate interpretations in our most critically ill patients.”

Zeto’s Founder and CEO, Aswin Gunasekar stated, “Breakthrough changes arise from the cumulative effect of years of gradual improvements. ONE is a culmination of 8+ years of customer centric product development by our industrious team. As our first-generation Wrap (WR19) headset sees increasing adoption for short-term EEGs, ONE strengthens our portfolio by democratizing access to continuous EEG brain monitoring and diagnostics. We anticipate ONE to notably advance EEG monitoring in critical care, outpatient and home settings.”

Christina Patterson, MD, Associate Professor of Pediatrics and the Director of the Epilepsy Center at UPMC Children’s Hospital of Pittsburgh said, “Zeto ONE will be a profound help to our pediatric patients by increasing access to much needed diagnostic and therapeutic interventions, particularly in Emergency Departments and Intensive Care Units where rapid application and complete EEG can make all the difference in getting a critically ill child the care they need.”

“Many hospitals in the world have no ability to obtain EEGs.,” said Robert S. Fisher, M.D., Ph.D., Director of the Stanford Epilepsy Center and former President of the American Epilepsy Society. “Zeto ONE will make it possible for them to do so. For hospitals and offices with EEG capabilities, ONE will make obtaining the EEG more efficient for the medical personnel and more comfortable for the patients.”

Zeto ONE is now available for sale. For inquiries, please call: +1 (866) 527-5549, +1 (833) ZETO EEG or email: sales@zetoinc.com

References:  

  1. Herman, S.T., et al. (2015). “J Clin Neurophysiol,” 32(2):87-95.
  2. Kolls, B.J., and Husain, A.M. (2007). “Epilepsia,” 48(5):959-65.
  3. Klem, G.H., Lüders, H.O., et al. (1999). “Guidelines of the International Federation of Clinical Physiology,” EEG Suppl. 52.
  4. Enabled by Encevis. Rommens, N., et al. (2018). “Improving staff response to seizures on the epilepsy monitoring unit with online EEG seizure detection algorithms,” Epilepsy & Behavior, July 2018.
  5. Hillman, J., et al. (2013). “National Library of Medicine,” 6(6).
  6. Madžar, D., et al. (2016). “J Neurol,” 263:485-491.

About Zeto, Inc.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology firm, is at the forefront of advancing EEG brain monitoring and diagnostics for healthcare. Offering wearable devices, Zeto makes brain monitoring accessible across various clinical settings including the ICU, ED, hospital, office, and home. Supported by a feature-rich cloud-based platform, Zeto provides nationwide monitoring and interpretation services rendered by neurologists, alongside AI-enabled notifications for conditions such as seizures and epilepsy. Zeto plans to expand its capabilities in the future to recognize and manage conditions such as depression and traumatic brain injury. 

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – PRNewswire

Zeto Announces Expert Jury for Its EEG Clinical Trial Sponsorship Program

SANTA CLARA, Calif., May 7, 2024 (Newswire.com) – Zeto, Inc., an innovative EEG brain monitoring company, is pleased to announce the distinguished members of the jury panel for its first clinical trial sponsorship program. The panel, comprising professionals from the fields of neurology and neuroscience research, will oversee the assessment and selection of clinical trials and research projects that align with Zeto’s mission to advance biomedical research and enhance patient care through innovative EEG applications.

Jury Panel Members:

Robert Fisher, MD, PhD – Dr. Fisher is the Director of the Stanford Epilepsy Center and is Zeto’s Chief Medical Advisor. He received research awards from the Klingenstein Foundation, EF, CURE and NIH. He has been named ‘Best Doctors in America’ since 1996 and received the Ambassador Award from the International League Against Epilepsy, the 2005 AES Service Award and the 2006 Annual Clinical Research Award. He is also the Past President of the American Epilepsy Society. His extensive experience and leadership in epilepsy research are invaluable to guiding the future of EEG technologies.

Michael Weisend, PhD – Dr. Weisend brings a multidisciplinary approach to the panel with his background in cognitive neuroscience, device development, and neuroimaging techniques. His work in academia, government, and industry, along with his innovative contributions to brain stimulation technologies, will provide a broad perspective on the potential applications of research topics in clinics using Zeto EEG. 

Pradeep Modur, MD – Dr. Modur is a board-certified epileptologist and a Professor of Neurology at Dell Medical School at The University of Texas, Austin. Most recently, he served as the Director of the Ascension Comprehensive Epilepsy Program and as the Chair of the Ascension’s National Epilepsy Service Line. Dr. Modur is active in research and innovation, serves as a reviewer for several journals, authored multiple board review books, and is a highly sought speaker at conferences. His national recognition as an expert in epileptic disorders makes him a critical asset to the jury.

“We are thankful to all the research teams who submitted their applications. We were thrilled to receive such high-quality proposals! Now it’s time for our accomplished panel to evaluate the submissions. The assessment includes several factors such as alignment with Zeto’s vision, the potential impact on patient care, and the innovative utilization of EEG,” says Florian Strelzyk, Chief Sales Officer at Zeto.

Zeto announced at the 2023 Society for Neuroscience Convention in Washington D.C. that it invites interested research teams to submit proposal pitches by April 15, 2024, and the company would sponsor up to three clinical trials using the Zeto EEG system. 

Important Dates:

Selection Completion: The rigorous selection process will commence in May and be completed by June 1st, 2024.

Public Announcement: The selected clinical research projects will be publicly announced no later than June 10th, 2024, on Zeto’s official website and social media channels.

Zeto is committed to fostering advancements in EEG technology and clinical research. Our high-caliber jury panel underscores our dedication to supporting meaningful and impactful scientific studies that can significantly improve patient outcomes.

About Zeto, Inc.

Zeto, Inc., is an award-winning, privately held medical technology company located in Santa Clara, CA, focused on transforming the way electroencephalography is done in clinical and research settings. Zeto’s revolutionary FDA-cleared EEG platform brings the traditional EEG procedure to the 21st century by offering the WR19, a zero-prep, wireless, easy-to-wear headset with active, dry electrodes that can be positioned as per the 10-20 system. The company plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials.

To learn more about Zeto’s products, please visit https://zeto-inc.com or email us at research@zetoinc.com.

Source – Newswire 

Zeto Successfully Completes SOC 2 Type II Audit for Its Cloud Platform, Demonstrating Commitment to Data Security

SANTA CLARA, Calif., March 18, 2024 (Newswire.com) – Zeto, Inc., a commercial-stage medical technology company transforming EEG brain monitoring in healthcare with its innovative EEG headset and advanced cloud platform, is proud to announce its renewal of SOC 2 Type II compliance. This critical milestone highlights Zeto’s commitment to the highest standards of security and compliance, in line with the stringent guidelines set forth by the American Institute of Certified Public Accountants (AICPA) for SOC for Service Organizations, also recognized as SSAE 18.

Achieving SOC 2 Type II compliance, with an unqualified opinion, serves as third-party industry validation that Zeto, Inc. provides enterprise-level security for customer data stored in its Cloud Platform. This accomplishment is a testament to Zeto’s unwavering commitment to data security and operational excellence, ensuring the highest standard of protection for customer information.

Aswin Gunasekar, Zeto’s founder and CEO said, “SOC Accreditation is more than a benchmark for Zeto; it’s a reflection of our deep commitment to security and privacy within the healthcare sector. By achieving this standard, we affirm our dedication to offering dependable and secure cloud services, tailored to meet the critical needs of hospitals and healthcare providers.”

Zeto Successfully Completes SOC 2 Type II Audit for Its Cloud Platform

An unqualified opinion in a SOC 2 Type II audit indicates that Zeto, Inc. manages data with the highest standard of security, providing peace of mind to both current and prospective customers about the company’s commitment to data protection and compliance.

About Zeto, Inc.

Zeto, Inc. is an award-winning, privately held medical technology company located in Santa Clara, CA, that is focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto’s revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. The company plans to leverage its hardware and software technology to improve noninvasive monitoring of the brain’s electrical activity and achieve better outcomes for neurological conditions such as epilepsy, sleep disorders, autism, stroke, and concussion.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – Newswire 

Zeto Adds New Chief Financial Officer to Accelerate Growth

SANTA CLARA, Calif., March 6, 2024 (Newswire.com) – Zeto, Inc., a commercial-stage medical technology company transforming EEG brain monitoring for healthcare with its innovative EEG headset and advanced cloud platform, today announced the appointment of Neway Redia as its new Chief Financial Officer. With a career spanning over 20 years, including 16 years at Siemens across multiple divisions and various countries, and last 4 years in leadership positions at medical technology startups, namely, Zap Surgical and Promaxo, Neway brings a wealth of experience and skill to help co-lead Zeto to its next stage of growth.

Aswin Gunasekar, Founder and CEO of Zeto, expressed his enthusiasm saying, “We are excited to welcome Neway Redia as our Chief Financial Officer, especially during a period of fast growth for Zeto. His diverse background, expertise, and strategic leadership are what our company needs at this pivotal phase of our journey. Under Neway’s guidance, we look forward to scaling our operations rapidly and creating the foundation for Zeto to be able to lead the industry. We are optimistic about achieving rapid market penetration with our popular EEG platform.”

Zeto announced the appointment of Neway Redia as its new Chief Financial Officer. 

On joining Zeto, Neway shared, “I am super excited to join Zeto at such an important phase. The company’s market potential is huge, promising extensive opportunities for growth and innovation. As CFO, I aim to provide financial and strategic leadership to Zeto, as we transform EEG technology which is due for a change, and secure leadership position in the brain monitoring market.”

Neway will be based out of Zeto’s office in Santa Clara, working closely with the company’s management team and the board of directors. 

About Zeto, Inc.

Zeto, Inc. is an award-winning, privately held medical technology company located in Santa Clara, CA, that is focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto’s revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. The company plans to leverage its hardware and software technology to improve noninvasive monitoring of the brain’s electrical activity and achieve better outcomes for neurological conditions such as epilepsy, sleep disorders, autism, stroke, and concussion.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – Newswire 

Zeto Achieves HITRUST Risk-Based, 2-year Certification Demonstrating the Highest Level of Information Protection Assurance

HITRUST Risk-Based, 2-year (r2) Certification validates Zeto is committed to strong cybersecurity and protecting sensitive data.

SANTA CLARA, Calif., February 26, 2024 (Newswire.com) – Zeto, Inc., a commercial-stage medical technology company transforming EEG brain monitoring in healthcare with its innovative EEG headset and advanced cloud platform, today announced its ZCP (Zeto Cloud Platform) has earned certified status by HITRUST for information security.

HITRUST Risk-based, 2-year (r2) Certification demonstrates that the organization’s ZCP (Zeto Cloud Platform) has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places Zeto, Inc. in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

Zeto Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection Assurance

“We’re proud to affirm our commitment to exceptional data protection and information security standards by securing the distinguished HITRUST r2 Certification,” said Aswin Gunasekar, Founder and CEO at Zeto, Inc.

“HITRUST certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST certification is considered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,” said Jeremy Huval, Chief Innovation Officer at HITRUST.

About Zeto, Inc.

Zeto, Inc. is an award-winning, privately held medical technology company located in Santa Clara, CA, that is focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto’s revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. The company plans to leverage its hardware and software technology to improve noninvasive monitoring of the brain’s electrical activity and achieve better outcomes for neurological conditions such as epilepsy, sleep disorders, autism, stroke, and concussion.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – Newswire 

Zeto Exhibits at Neuroscience 2023 and Will Sponsor EEG Clinical Trials

SANTA CLARA, Calif., November 13, 2023 (Newswire.com)

Zeto, Inc., an innovative EEG brain monitoring company, is excited to make two significant announcements as the company continues to expand the boundaries of brain monitoring.

Zeto is proud to announce its inaugural participation at the Neuroscience 2023 conference hosted by the Society for Neuroscience. Taking place from November 11-15, 2023, at the Walter E. Washington Convention Center in Washington, D.C., this event will bring together over 30,000 scientists, researchers, and clinicians making it the largest conference in neuroscience.

“At Zeto, we’ve consistently delivered substantial value to our clinical partners in hospitals and private practices. Now, we’re excited to bring the convenience of Zeto EEG to the forefront of your clinical research journey. The Society for Neuroscience conference is a remarkable opportunity for us to connect with the global scientific community and facilitate the use of EEG for brain monitoring,” said Florian Strelzyk, PhD, Chief Sales Officer at Zeto. “Zeto understands your need for ease of use, comfort, and a refined experience with EEG technology. We believe our products will unlock a world of new opportunities, enabling EEG researchers to step out of the lab and into research environments closely aligned with their interests. We invite attendees to visit our booth #2430 in the Exhibitor Hall to discover and experience our innovative EEG solutions for clinical trials and research.”

Zeto reaffirms its commitment to increasing accessibility to brain monitoring by sponsoring up to three EEG clinical trials in 2024. These trials aim to support advanced clinical research and bring innovative applications closer to full real-world implementation.

Each sponsored clinical trial will enjoy the following benefits:

  • WR19 EEG System: Each sponsored clinical trial will benefit from Zeto’s EEG device, an FDA-cleared, wireless, portable, dry-electrode, full 10-20 montage EEG headset with high-quality data collection and a fast and comfortable 5-minute setup.
  • Cloud Access: Access to HIPAA-compliant, cyber-security cleared cloud platform for efficient data storage, remote access, EDF export, and real-time LSL data streaming.
  • Disposable Electrodes: Zeto will provide disposable electrodes for up to 100 EEG recordings in each clinical trial. These electrodes are designed for comfort and ease of use, enhancing the participant experience.
  • TTL-based Triggering for ERP Recordings: If required, the Zeto system will include an additional component for real-time TTL-based triggering for evoked potentials, along with additional stimulus presentation software and hardware.
  • Training and Support: To ensure a smooth and successful implementation of Zeto’s EEG solutions, the company provides training and ongoing support to clinical trial teams.

To participate in this opportunity, interested research teams are invited to submit a 2-page proposal or project pitch by March 31st, 2024. Further details and submission guidelines can be found on the Zeto Clinical Trials Sponsorship webpage.

Zeto is dedicated to enhancing the accessibility of brain monitoring. For more information about Zeto, please visit Zeto’s website. 

Source – Newswire 

Exploring Zeto’s Dry EEG Headset: Advantages for Medical Research

Zeto has been providing value to clinical customers in hospitals and private practices for some time now. However, we have recently extended our offerings to CROs and cutting-edge researchers in the field of medical research. A. Mark Mento, director of enterprise sales here at Zeto, discusses the advantages of Zeto’s dry EEG headset for researchers, highlighting its ease of use, comfort, and potential to bring EEG out of the lab and into the medical research environment.

Zeto recently introduced new features for clinical research applications. Where does Zeto fit into the research world?

Zeto offers a unique solution within the research world as our EEG for research represents a combination of technology from both the medical device and academic research space.

Our EEG for clinical research is particularly useful for studies that involve participants from clinical populations, or are conducted in a clinical environment. The Zeto system is fully FDA-cleared, ensuring compliance with rigorous medical standards for data quality and privacy, ensuring an easier Institutional Review Board (IRB) process.

Because the Zeto system conforms to medical standards regarding electrode position and data quality, it is compatible with large clinical EEG datasets. Researchers utilizing these databases to train biomarkers and machine learning algorithms will be able to apply their work directly to Zeto data.

The Zeto system achieves medical conformity while allowing a much faster and more comfortable setup without requiring gel, scalp prep. The system allows for real-time data streaming via LSL, remote data access via API, and high-fidelity triggering for visual evoked potential tests.

What specific advantages does Zeto offer to researchers over conventional wet electrode systems in terms of usability?

Gel-based systems take a while to set up and are uncomfortable for participants. They usually require some degree of scalp preparation (scratching the electrode site to remove dead skin and other material) and they leave gel in the hair that must be showered out. 

When gel-based EEGs are used for medical research, it is difficult for a participant to leave a test and return to class or work. Additionally, medical-style gel EEG systems require a qualified technologist to measure the head and to apply electrodes in the correct place.

The Zeto EEG system provides two advantages over this process.

  1. First, the system uses disposable electrodes with a dry soft-tip coating. This allows for proper electrical conductivity with the scalp without requiring prep or gel.
  2. Second, the headset is mechanically adjustable to the head size of the participant, ensuring that the electrodes are in the correct 10-20 positions. This feature allows individuals without knowledge of electrode replacement and EEG to set up the system accurately with minimal training.

Together, these features allow the system to be set up very quickly on most participants, typically within 5 minutes. It is also much more comfortable for the participant and when the test is over the system is removed instantly with no residual gel left behind.

What research-specific features does the system include?

We offer a range of specific features on our eeg for medical research that cater to the unique and specific needs of researchers.

For example, the system includes a comprehensive API for both real-time local data streaming, and cloud-based data access. Zeto EEG data can be integrated directly into experiments, utilizing the full range of data access capabilities.

The Zeto platform can also accept epoch trigger inputs for event-related potentials (ERPs) and other timing-sensitive experiments, expanding the possibilities for research applications.

Overall, Zeto provides cutting edge features for both clinical and research applications, offering researchers enhanced usability, accurate data acquisition, and the flexibility to conduct various experiments.

Can you provide examples of potential future applications of EEG technology in research, and how Zeto’s system might contribute to advancements in these areas?

EEG technology is expanding in medical and mental health applications beyond the traditional domains of epilepsy and stroke.

Researchers are increasingly exploring the use of machine learning techniques applied to EEG data for potential screening, diagnostics and interventions. Information from EEGs used for research could help diagnose certain conditions, or to evaluate and quantify the effects and success of certain treatment paradigms.

Zeto’s EEG system is well-positioned to contribute to these advancements in several ways.

  1. First, the Zeto EEG headset has direct medical applicability. Since data from the headset is functionally identical to traditional medical EEG in terms of data quality and electrode position, any pioneering research conducted using Zeto’s system can directly translate to the clinical market.
  2. Second, Zeto’s system provides a practical and comfortable solution for running participants in a clinical environment. It offers ease of setup and enhanced practicality, streamlining the process for researchers and facilitating data collection in clinical settings.

Can you share some information about Zeto’s current research customers and the successful projects?

The Zeto EEG for research is new in the research space, specifically. But we already have a diverse range of research customers.

Our products have been used in clinical trials on three continents (and counting). Additionally, we have established collaborations and installed equipment in numerous academic research labs in universities and teaching hospitals.

These partnerships highlight the growing adoption of Zeto’s system within the research community, leading to successful projects across various domains.

What types of support or training Zeto provides to researchers who are new to working with EEG technology?

For Zeto systems purchased in North America, we provide on-site training. Our dedicated customer success team is readily available to address any inquiries or support-related questions promptly.